Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price shot up 25.6% during mid-day trading on Thursday . The company traded as high as C$0.29 and last traded at C$0.27. 1,058,771 shares traded hands during trading, an increase of 65% from the average session volume of 640,063 shares. The stock had previously closed at C$0.22.
Hemostemix Price Performance
The company has a market cap of C$27.01 million, a price-to-earnings ratio of -15.50 and a beta of 0.20. The firm has a fifty day simple moving average of C$0.11 and a 200 day simple moving average of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Transportation Stocks Investing
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Following Congress Stock Trades
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
